Bonafide for Menopause: Who It's Actually Best For (and Who Should Look Elsewhere)

What Is Bonafide and What Does It Actually Sell?

Bonafide markets itself as a science-backed, hormone-free brand for menopause. The company sells a line of OTC supplements targeting hot flashes, sleep disruption, vaginal dryness, mood changes, and cognitive fog. No prescription is required for any product, and everything ships direct-to-consumer.

The flagship product is Relizen, a purified pollen extract (Sérélys, also sold as Femal in Europe) studied in several randomized controlled trials. Other products in the line include Clairvee (vaginal microbiome support), Revaree (hyaluronic acid vaginal insert), and Wile-adjacent-style mood and sleep formulas. Revaree is perhaps the second most clinically supported product, given the body of evidence behind vaginal hyaluronic acid for genitourinary syndrome of menopause (GSM).

The brand does not offer compounded bioidentical hormones, FDA-approved hormone therapies, or prescription medication of any kind. That distinction matters clinically.

What "Non-Hormonal" Actually Means Here

Non-hormonal means the products contain no exogenous estrogen, progesterone, testosterone, or DHEA. Some competing brands use phytoestrogens (soy isoflavones, red clover), which bind weakly to estrogen receptors. Bonafide avoids those entirely. For women with estrogen-receptor-positive breast cancer history or who are on aromatase inhibitors, this distinction is worth noting, though it does not guarantee safety and oncology team approval remains necessary before adding any supplement.

How the Subscription Model Works

Bonafide ships on a monthly or quarterly subscription. Cancellation is self-service online. The subscription model is standard for D2C supplement brands and not inherently problematic, but it means costs accumulate over time. A woman taking Relizen plus Revaree spends roughly $80-$120 per month, which is not trivial and is rarely covered by insurance.

The Science Behind Bonafide's Key Products

Relizen (Pollen Extract) for Hot Flashes

Relizen's active ingredient is a non-estrogenic, non-phytoestrogenic standardized pollen extract. The proposed mechanism involves modulating serotonin and beta-endorphin pathways, rather than estrogen receptors, which is why researchers have studied it in women who cannot use hormones.

A 2005 randomized trial published in Gynecological Endocrinology found that the pollen extract reduced hot flash frequency by approximately 73% versus 38% in the placebo group over 3 months in postmenopausal women. A systematic review in Maturitas (2016) pooled data from multiple European RCTs and concluded the extract significantly reduced vasomotor symptom frequency and severity, with a favorable safety profile. The evidence is genuinely promising for mild-to-moderate hot flashes.

However, several caveats apply:

• Most trials were conducted in Europe under the product name Femal or Sérélys, with small-to-moderate sample sizes (typically 50-100 women per arm).
• Women with severe vasomotor symptoms (defined as 7 or more moderate-to-severe hot flashes per day) were underrepresented.
• No head-to-head trial compares pollen extract directly to FDA-approved menopausal hormone therapy or to the non-hormonal prescription option fezolinetant (Veozah).

The Menopause Society (formerly NAMS) 2023 position statement on non-hormonal management lists pollen extract as having "some evidence" but does not give it the same recommendation strength as fezolinetant, paroxetine (Brisdelle), or cognitive behavioral therapy for vasomotor symptoms. That grading gap is clinically meaningful.

Revaree (Vaginal Hyaluronic Acid) for GSM

Vaginal hyaluronic acid is the ingredient with the strongest non-hormonal evidence base for GSM, and Revaree uses it as an insertable suppository.

A 2020 systematic review in Menopause covering five RCTs found hyaluronic acid vaginal preparations comparable to low-dose topical estrogen for relieving vaginal dryness and dyspareunia in postmenopausal women. ACOG Practice Bulletin No. 141 acknowledges vaginal moisturizers and lubricants as first-line options for women who prefer non-hormonal GSM management.

For post-menopausal women who have vaginal dryness, irritation, or painful sex but cannot use or prefer not to use vaginal estrogen or ospemifene, Revaree is a clinically reasonable choice.

Other Products: Thinner Evidence

Clairvee targets vaginal microbiome support with Lactobacillus strains and boric acid. Vaginal probiotic data is emerging but inconsistent, and a 2019 Cochrane review on probiotics for vaginal flora found insufficient evidence to support routine use for non-BV indications. The sleep and mood formulas contain standard ingredients like magnesium and ashwagandha, with some ingredient-level trial data but no Bonafide-specific trial evidence.

Is Bonafide Legit? An Honest Assessment

Applying a three-tier framework to evaluate supplement brands in women's health:

Tier 1: Ingredient-level RCT data in the target population. Relizen and Revaree meet this bar. The pollen extract and vaginal hyaluronic acid each have multiple peer-reviewed randomized trials in peri- and post-menopausal women.

Tier 2: Plausible mechanism, early clinical data. Several Bonafide secondary products land here.

Tier 3: Theoretical or general-population data only. Some of the mood and sleep adjuncts fall into this tier.

So: Bonafide is not a scam. The company cites real research. But citing a trial is not the same as the trial proving what the marketing implies. No Bonafide product has gone through the FDA drug approval process, which requires phase III trials demonstrating efficacy and safety for a specific indication. Products are regulated as dietary supplements, which carry a substantially lower evidence bar than prescription drugs.

Women should understand this distinction before spending $80 per month.

What "FDA-Cleared" Claims Really Mean

Bonafide uses careful language. Revaree is marketed as an FDA-cleared medical device (as a vaginal suppository delivery form), not as an FDA-approved drug. The drug approval process and device clearance are categorically different. Medical device clearance (510k pathway) does not evaluate clinical efficacy in the way drug approval does. That does not make Revaree ineffective, but the label should not be read as an FDA efficacy endorsement.

Bonafide vs. Alternatives: Where It Fits in the Non-Hormonal Field

Prescription Non-Hormonal Options

If you have moderate-to-severe vasomotor symptoms and cannot use hormone therapy, prescription options have stronger regulatory evidence:

• Fezolinetant (Veozah), an NK3 receptor antagonist, received FDA approval in May 2023 and reduced moderate-to-severe hot flash frequency by approximately 59% at 12 weeks versus 40% for placebo in the SKYLIGHT 1 trial. It requires a prescription and liver function monitoring.
• Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved SSRI specifically for vasomotor symptoms, and The Menopause Society's 2023 clinical guidelines list SSRIs/SNRIs as a recommended non-hormonal class with Level I evidence.
• Cognitive behavioral therapy (CBT) for hot flashes showed a 73% responder rate in the MENOS 1 trial and carries a strong recommendation in both NAMS and NICE guidelines.

OTC Supplement Competitors

Other non-hormonal OTC brands (Estroven, Amberen, Dr. Kellyann) mostly rely on phytoestrogens or general antioxidant blends. Bonafide's advantage over most OTC competitors is the absence of phytoestrogens and the pollen-extract ingredient's stronger RCT footing compared to, say, black cohosh, which has a mixed and contradictory evidence record in the NAMS literature.

Menopausal Hormone Therapy

For women without contraindications, The Menopause Society's 2022 Hormone Therapy Position Statement states that hormone therapy "remains the most effective treatment for vasomotor symptoms" and is appropriate for healthy women under age 60 or within 10 years of menopause onset. Bonafide is not a substitute for HRT when HRT is medically appropriate. Choosing a supplement over HRT to avoid perceived risks should prompt a shared clinical decision-making conversation, not a D2C purchase.

Who Bonafide Is Right For

The Strong-Fit Patient

Bonafide is most appropriate for you if:

• You are in perimenopause or early post-menopause (within 5 years of final menstrual period) with mild-to-moderate hot flashes (fewer than 7 per day) or vaginal dryness.
• You have a personal preference against hormones after an informed discussion with your clinician.
• You have a contraindication to systemic estrogen, such as personal history of estrogen-receptor-positive breast cancer, active deep vein thrombosis, or unexplained vaginal bleeding under evaluation.
• You are already using HRT or a prescription non-hormonal drug and want adjunctive vaginal moisture support (Revaree may be appropriate here).
• You want something to try while waiting for a menopause specialist appointment, with the understanding that it may partially help and is unlikely to cause harm.

The Moderate-Fit Patient

• Late perimenopause with irregular cycles and emerging sleep disruption. Some women in this window find pollen extract helpful, though the trial data is almost entirely in post-menopausal women.
• Women with mild GSM who want a low-cost first step before escalating to prescription vaginal estrogen, ospemifene, or prasterone (Intrarosa).

Who Should Look Elsewhere

Bonafide is a poor fit if:

• Your hot flashes are severe (7 or more moderate-to-severe episodes per day). Fezolinetant, HRT, or an SSRI/SNRI is more appropriate.
• You have untreated GSM with significant dyspareunia or urinary symptoms. Vaginal estrogen or prescription options have stronger and faster evidence.
• You are post-menopausal with cardiovascular risk factors that warrant a conversation about the full cardiovascular risk-benefit picture of HRT, not a decision delegated to a supplement.
• You are on tamoxifen for breast cancer. Some ingredients in multi-component supplements may interact with tamoxifen metabolism via CYP2D6 pathways, and your oncology team must be consulted before adding anything.

Pregnancy, Lactation, and Contraception Considerations

Bonafide products are formulated for peri- and post-menopausal women. They have not been studied in pregnant or breastfeeding women, and no safety data exists for these populations.

Pregnancy: If you are in perimenopause and still ovulating, pregnancy remains possible until 12 months after your final menstrual period. Pollen extract, the active ingredient in Relizen, has no human pregnancy safety data. ACOG recommends reliable contraception until menopause is confirmed in perimenopausal women who do not want pregnancy. Do not take Relizen or other Bonafide supplements during pregnancy.

Lactation: No lactation transfer studies exist for pollen extract or the other Bonafide ingredients in the context of late postpartum or induced lactation. Avoid use while breastfeeding.

Contraception requirement: Perimenopause does not equal infertility. If you are using Bonafide products because you are avoiding hormones but still at risk of pregnancy, discuss a non-hormonal contraceptive method (copper IUD, barrier methods) or a progestin-only option with your clinician.

Women on tamoxifen or aromatase inhibitors: Pollen extract does not appear to be estrogenic based on receptor-binding assays, but comprehensive interaction data with these oncologic agents is lacking. A 2012 study in Maturitas found no estrogenic activity of the pollen extract in vitro, which is reassuring but not definitive. Your oncologist must clear any supplement use.

How Much Does Bonafide Cost, and Is It Worth It?

Relizen retails at approximately $50-$60 per month on subscription. Revaree runs $35-$45 per month. Together, you are spending $85-$105 monthly, or roughly $1,000-$1,260 per year, with no insurance coverage.

Fezolinetant (Veozah), by comparison, costs approximately $550 per month without insurance but may be covered under some plans. Low-dose oral estrogen plus micronized progesterone can cost $30-$60 per month with insurance coverage, often less with generic formulations.

Is the cost justified? For women with mild symptoms and a strong preference for non-hormonal options, Relizen at $50/month for a 3-month trial is a reasonable, low-risk expenditure. The 2016 Maturitas systematic review showed meaningful symptom reduction in 3 months for a majority of women in the trials. If you see no improvement at 3 months, there is no clinical rationale to continue.

Revaree at $35-$45/month compares favorably to prescription vaginal moisturizers in cost and has comparable efficacy data to low-dose vaginal estrogen for the symptom of dryness (though vaginal estrogen does more for urogenital atrophy broadly).

A 3-month trial of Relizen with a reassessment at 90 days is a reasonable approach. If you are spending $600+ per year with no measurable improvement, that budget is better directed toward a telehealth menopause specialist visit and a prescription option.

Sex-Specific Physiology: Why the Same Supplement Hits Differently Across Life Stages

Perimenopause (Roughly Ages 40-51)

Estrogen levels fluctuate wildly rather than declining linearly. Hot flashes in perimenopause often co-occur with menstrual irregularity, mood lability, and sleep disruption. Trial data for pollen extract is predominantly in post-menopausal women. Perimenopausal hot flashes driven by estrogen surges and drops may respond differently than the more stable low-estrogen environment of post-menopause. This is an under-studied area, and extrapolating post-menopausal trial data to perimenopause is not fully supported by the evidence.

Post-Menopause (12+ Months After Final Period)

This is the population in whom Relizen and Revaree have been studied. If you are in this group with mild-to-moderate symptoms, Bonafide's evidence base is most directly applicable to you.

Surgical Menopause

Women who have had bilateral oophorectomy experience an abrupt, severe drop in estrogen rather than a gradual transition. Vasomotor symptoms are often more intense. The limited trial evidence for pollen extract was almost entirely in natural menopause populations. For surgical menopause, HRT is the guideline-recommended first-line treatment for symptom management and bone protection. Bonafide alone is likely insufficient for this group unless HRT is specifically contraindicated.

PCOS and Premature Ovarian Insufficiency (POI)

Women with PCOS who enter menopause earlier than average or women with POI (menopause before age 40) face different cardiovascular and bone health risks than typical menopausal women. ACOG Practice Bulletin No. 234 and NAMS guidance both recommend HRT in POI patients until at least age 51 for cardiovascular and bone protection. A supplement is not an adequate substitute in POI. If you have POI, the question of what to take for symptoms is secondary to whether you are on appropriate hormone replacement for long-term health protection.

Evidence Gaps: What We Do Not Know

Women have historically been underrepresented in dietary supplement trials, and menopause supplement research specifically tends to suffer from small sample sizes, short follow-up periods, and industry funding. The trials behind pollen extract were mostly conducted in Europe with modest sample sizes and short durations (12-24 weeks). No long-term safety data (2+ years) exists for Relizen. No trial has examined cognitive outcomes, cardiovascular markers, or bone density with any Bonafide product.

The Menopause Society acknowledges that "many women use complementary and alternative therapies... Often without disclosure to their clinicians," and notes that "evidence for most non-hormonal therapies remains limited." That is not a dismissal of all supplements, but it is a calibration of appropriate confidence.

Tell your clinician you are using or considering these products. That conversation matters, especially if you are being evaluated for persistent symptoms that might warrant escalation to prescription treatment.

A Clinician Note on Supplement Disclosure

"One of the most common gaps I see in my menopause patients is the supplement blind spot," says Elena Vasquez, MD, WomanRx editorial board member and NAMS-certified menopause practitioner. "Women are often taking two or three OTC products from brands like Bonafide alongside prescription medications and not mentioning it, sometimes because they assume non-hormonal means no interaction risk. That assumption is not always correct, particularly in women on oncologic therapies or anticoagulants."